Modifications in plasma lipoprotein concentration and lipid composition regulate the biological activity of hydrophobic drugs

Journal of Pharmacological and Toxicological Methods

Volumn 36, Issue 1, 1996, Pages 1-11

  Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Amphotericin B; Annamycin; Cyclosporine; Dyslipidemia; Lipid transfer protein; Lipoproteins; Nystatin

Indexed keywords

AMPHOTERICIN B; ANNAMYCIN; CYCLOSPORIN; LIPID TRANSFER PROTEIN; NYSTATIN;

CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DRUG DOSE; DRUG PROTEIN BINDING; DYSLIPIDEMIA; HUMAN; HYDROPHOBICITY; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; NEPHROTOXICITY; NONHUMAN; PLASMA CLEARANCE; REVIEW;

ANIMALIA;

EID: 0030246906     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/1056-8719(96)00054-8     Document Type: Review

References (68)

1. Albers JJ, Tollefson JH, Chen C-H, Steinmetz A (1984) Isolation and characterization of human lipid transfer proteins. Arteriosclerosis 4:49-58.
2. Alexopoulos CG, Blatsios B, Avgerinos A (1987) Serum lipids and lipoprotein disorders in cancer patients. Cancer 60:3065-3070.
3. Andrade RJ, Lucena MI, Gozales-Correa JA, Garcia-Arias C, Gonzales-Santos P (1993) Short-term effect of various doses of cyclosporin A on plasma lipoproteins and its distribution in blood: An experimental study. Transplant Proc 25:2973-2977.
4. Arnadottir M, Thysell H, Nilsson-Ehle P (1991) Lipoprotein levels and post-heparin lipase activities in kidney transplant recipients: Ciclosporin-versus non-ciclosporin-treated patients. Am J Kidney Dis 17:700-707.
5. Awni WM, Sawchuk RJ (1985) The pharmacokinetics of cyclosporine. II. Blood plasma binding and distribution. Drug Metab Disp 13:133-138.
6. Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV (1989) Long-term cyclosporine pharmacokinetic changes in renal transplant recipients. Clin Pharmacol Ther 45:41-51.
7. Barter PJ, Jones ME (1980) Kinetic studies of the transfer of esterified cholesterol between human plasma low and high density lipoproteins. J Lipid Res 21:238-245.
8. Bierer BE, Hollander G, Fruman D, Burakoff SJ (1993) Cyclosporin A and FK-506: Molecular mechanisms of immunosuppressive probes for transplantation biology. Curr Opin Immunol 5:763-773.
9. Brajtburg J, Elberg S, Bolard J, Medoff G (1984) Interaction of plasma proteins and lipoproteins with amphotericin B. J Infect Dis 149: 986-992.
10. Brunner LJ, Vadiei K, Luke DR (1988) Cyclosporine disposition in the hyperlipidemic rat model. Res Comm Chem Path Pharmacol 59: 339-348.
11. Brunner LJ, Iyer LV, Vadiei K, Weaver WV, Luke DR (1989) Cyclosporine pharmacokinetics and effect in the Type I diabetic rat model. Eur J Drug Metab Pharmacokinet 14:287-292.
12. Brunner LJ, Luke DR, Lautersztain J, et al. (1990) Single-dose Cyclosporine pharmacokinetics in various biological fluids of patients receiving allogenic bone marrow transplantation. Ther Drug Monit 12:134-138.
13. Budd D, Ginsberg H (1986) Hypocholesterolemia and acute myelogenous leukemia: Association between disease activity and plasma low-density lipoprotein cholesterol concentrations. Cancer 58:1361-1365.
14. Cassidy S, Wasan KM (1996c) Decreases in high density lipoprotein esterified cholesterol content alters the plasma distribution of annamycin and nystatin. Pharm Res Submitted.
15. Chabot GG, Pazdur R, Valeriote FA, Baker LH (1989) Pharmacokinetics and toxicity of continuous infusion of amphotericin B in cancer patients. J Pharm Sci 78:307-310.
16. Chao FC, Efron B, Wolf P (1975) The possible prognostic usefulness of assessing serum proteins and cholesterol in malignancy. Cancer 35:1223-1229.
17. Christison R (1830) Case study of lipoproteins in atherosclerosis, Edinburg Medical Surgical Journal 33:276-278.
18. Cushley RJ, Treleaven WD, Pramar YI, et al. (1987) Surface diffusion in human serum lipoproteins. Biochem Biophys Res Commun 146:1139-1145.
19. Davis RA (1991) Biochemistry of Lipids, Lipoproteins, and Membranes. New York: Elsevier.
20. de Groen PC (1988) Cyclosporin, low-density lipoprotein, and cholesterol. Mayo Clin Proc 63:1012-1021.
21. de Smidt PC, van Berkel TJC (1990) Prolonged serum half-life of antineoplastic drugs by incorporation into the low density lipoproteins. Cancer Res 50:7476-7482.
22. Durrington PN (1989) Hyperlipidemia: Diagnosis and Management. London: Wright Press.
23. Feingold KR, Krauss RM, Pang M, et al. (1993) The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinology 76:1423-1431.
24. Fielding PE, Fielding CJ (1991) Biochemistry of Lipids, Lipoproteins, and Membranes. New York: Elsevier Press.
25. Gardier AM, Mathe D, Guedeney X, et al. (1993) Effects of plasma lipid levels on blood distribution and pharmacokinetics of cyclosporin A. Ther Drug Monit 15:274-280.
26. Gibaldi M, Perrier D (1982) One-compartment model. Pharmacokinetics 15:1-42.
27. Groener JEM, Van Rozen AJ, Erkelens DW (1984) Cholesteryl ester transfer activity. Localization and role in distribution of cholesteryl ester among lipoproteins in man. Atherosclerosis 50:261-271.
28. Grunfeld C, Pang M, Doerrler W, et al. (1992) Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinology 74:2045-2051.
29. Harmony JAK, et al. (1986) Biochemistry and Biology of Plasma Lipoproteins. New York: Marcel Dekker.
30. Hughes TA, Gaber AO, Montgomery CE (1991) Plasma distribution of cyclosporine within lipoproteins and "in vitro" transfer between very-low-density lipoproteins, low-density lipoproteins, and high-density lipoproteins. Ther Drug Monit 13:289-295.
31. Ihm J, Ellsworth JL, Chataing B, Harmony JAK (1982) Plasma protein-facilitated coupled exchange of phosphatidylcholine and cholesteryl ester in the absence of cholesterol esterification. J Lipid Res 23:1328-1335.
32. Jarnagin AS, Kohr W, Fielding C (1987) Isolation and specificity of a Mr 74,000 cholesteryl ester transfer protein from human plasma. Proc Natl Acad Sci USA 84:1854-1860.
33. Kahan BD (1990) Cyclosporine. N Engl J Med 321:1725-1738.
34. Kasiske BL, Awni WM, Heim-Duthoy KL, Rose M, Rao UK, Bloom P, Wey A, Andrisevle J, Odland M, Andersen RC (1988) Alterations in cyclosporine pharmacokinetics after renal transplantation are linked to rapid increases in hematocrit, lipoproteins, and serum protein. Transplant Proc 20:485-486.
35. Koldin MH, Kobayashi GS, Brajtburg J, Medoff G (1985) Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity to rabbits. Antimicrob Agents Chemother 28:144-145.
36. Krieger M (1983) The use of amphotericin B to detect inhibitors of cellular cholesterol biosynthesis. Anal Biochem 135:383-391.
37. Kritchevsky SB, Wilcosky TC, Morris DL, et al. (1991) Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer. Cancer Res 51:3198-3203.
38. Lemaire M, Tillement JP (1982) Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol 34:715-718.
39. Lopez-Berestein G (1988) Liposomes as carriers of antifungal drugs. Annals New York Acad Sci 544:590-597.
40. Luke DR, Brunner LJ, Lopez-Berestein G, Yau JC (1992) Pharmacokinetics of cyclosporine in bone marrow transplantation: Longitudinal characterization of drug in lipoprotein fractions. J Pharm Sci 81:208-211.
41. Luke DR (1992) Immunosuppressive effect of cyclosporine in the hyperlipidemic rat mode. Biopharm Drug Dispos 13:635-645.
42. Mbewu A, Durrington PN (1990) Lipoproteins involved in tissue repair. Atherosclerosis 85:1-8.
43. Morton RE, Zilversmit DB (1982) Purification and characterization of lipid transfer protein(s) from human lipoprotein-deficient plasma. J Lipid Res 23:1058-1067.
44. Morton RE, Zilversmit DB (1983) Inter-relationships of lipid transferred by the lipid transfer protein isolated from human lipoprotein-deficient plasma. J Biol Chem 258:11751-11756.
45. Morton RE (1990) Interaction of lipid transfer protein with plasma lipoproteins and cell membranes. Experimentia 46:552-560.
46. Niederberger W, Lemaire M, Maurer G, Nussbaumer K, Wagner O (1983) Distribution and binding of cyclosporine in blood and tissue. Transplant Proc 15:2419-2421.
47. Pontain DR, Sun D, Brim JD, et al. (1989) Inhibition of HIV replication by liposomal-amphotericin B. Antiviral Res 13:119-125.
48. Rajaram OV, White GH, Barter PJ (1980) Partial purification and characterization of a triacylglycerol-transfer protein from rabbit serum. Biochim Biophys Acta 617:383-340.
49. Rodl S, Khoshsorur G (1990) Binding of cyclosporine A to human serum lipoproteins. Transplant Proc 22:287-288.
50. Rowland M, Tozier TN (1989) Distribution kinetics. Clin Pharm 3:297-438.
51. Sgoutas D, MacMahon W, Love A, Jerkunica I (1986) Interaction of cyclosporin A with human lipoproteins. J Pharm Pharmacol 38:583-588.
52. Son Y-SC, Zilversmit DB (1986) Increased lipid transfer activities in hyperlipidemic rabbit plasma. Arteriosclerosis 6:345-354.
53. Tall AR, Abreau E, Shuman J (1983) Seperation of a plasma phospholipid transfer protein from cholesterol ester/phospholipid exchange protein. J Biol Chem 258:2174-2178.
54. Umeki S (1993) Decreases in serum cholesterol levels in advanced lung cancer. Respiration 60:178-181.
55. Vitols S, Gahrton G, Ost A, Peterson A (1984) Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood 63:1186-1193.
56. Vitols S, Gahrton G, Bjorkholm M, et al. (1985) Hypocholesterolemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumor cells: Evidence from studies in patients with leukemia. Lancet iv:1150-1154.
57. Vitols S, Angelin B, Ericsson S, et al. (1990) Uptake of low density lipoproteins by human leukemic cells in vivo: Relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc Natl Acad Sci USA 87:2598-2602.
58. Warren RJ, Ebert DL, Barter PJ, Mitchell A (1991) The regulation of hepatic lipase and cholesteryl ester transfer protein activity in the cholesterol fed rabbit. Biochim Biophys Acta 1086:354-358.
59. Wasan KM, Vadiei K, Lopez-Berestein G, Luke DR (1990) Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J Infect Dis 161:562-566.
60. Wasan KM, Brazeau GA, Keyhani A, et al. (1993) Role of liposome composition and temperature on the distribution of amphotericin B in serum lipoproteins. Antimicrob Agents Chemother 37:246-250.
61. Wasan KM, Rosenblum MG, Cheung L, Lopez-Berestein G (1994a) Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrobial Agents Chemother 38:223-227.
62. Wasan KM, Morton RE, Rosenblum MG, Lopez-Berestein G (1994b) Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high density lipoproteins: Role of lipid transfer protein. J Pharm Sci 83:1006-1010.
63. Wasan KM, Grossie VB Jr., Lopez-Berestein G (1994c) Concentrations in serum and tissue distribution of free and liposomal amphotericin B in rats on continuous Intralipid infusion. Antimicrob Agents Chemother 38:2224-2226.
64. Wasan KM, Perez-Soler R (1995) Distribution of free and liposomal annamycin within human plasma is regulated by plasma triglyceride concentrations but not by lipid transfer protein. J Pharm Sci 84:1094-1100.
65. Wasan KM, Morton RE (1996) Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin. Pharm Res 13:462-468.
66. Wassef R, Cohen Z, Langer B (1986) In vivo interaction of cyclosporine and intralipid. Transplantation 41:266-268.
67. Wiederrecht G, Lam E, Hung S, Martin M, Sigal W (1993) Mechanism of action of FK-506 and cyclosporin A. Ann NY Acad Sci 696:9-19.
68. Yamada N, Shames DM, Havel RJ (1987) Effect of low density lipoprotein receptor deficiency on the metabolism of apolipoprotein B-100 in blood plasma. Kinetic studies in normal and Watanabe heritable hyperlipidemic rabbits. J Clin Invest 80:507-515.